Vapotherm, Inc. (VAPO)
USD 2.17
(-0.46%)
USD 2.17
(-0.46%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | -34.35 Million USD | 54.68% |
| 2022 | -100.39 Million USD | -41.48% |
| 2021 | -52.4 Million USD | -34.2% |
| 2020 | -43.01 Million USD | 14.1% |
| 2019 | -44.88 Million USD | -26.99% |
| 2018 | -37.23 Million USD | -28.83% |
| 2017 | -27.23 Million USD | -29.39% |
| 2016 | -20.89 Million USD | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q2 | -4.32 Million USD | -89.04% |
| 2024 Q1 | -4.27 Million USD | -10.0% |
| 2023 Q4 | -3.63 Million USD | 64.63% |
| 2023 Q2 | -8.93 Million USD | 34.42% |
| 2023 Q1 | -13.62 Million USD | 14.48% |
| 2023 Q3 | -10.27 Million USD | -14.95% |
| 2023 FY | - USD | 54.68% |
| 2022 Q4 | -15.93 Million USD | 16.74% |
| 2022 Q1 | -18.52 Million USD | -5.64% |
| 2022 FY | - USD | -41.48% |
| 2022 Q2 | -19.71 Million USD | -6.41% |
| 2022 Q3 | -19.13 Million USD | 2.94% |
| 2021 FY | - USD | -34.2% |
| 2021 Q3 | -11.54 Million USD | 24.41% |
| 2021 Q2 | -15.27 Million USD | -88.57% |
| 2021 Q1 | -8.09 Million USD | 34.08% |
| 2021 Q4 | -17.53 Million USD | -51.92% |
| 2020 FY | - USD | 14.1% |
| 2020 Q4 | -12.28 Million USD | -23.48% |
| 2020 Q1 | -11.47 Million USD | 8.3% |
| 2020 Q3 | -9.94 Million USD | -75.75% |
| 2020 Q2 | -5.66 Million USD | 50.67% |
| 2019 Q1 | -11.31 Million USD | -4.97% |
| 2019 Q4 | -12.51 Million USD | -18.21% |
| 2019 Q3 | -10.58 Million USD | 0.81% |
| 2019 Q2 | -10.67 Million USD | 5.63% |
| 2019 FY | - USD | -26.99% |
| 2018 Q2 | -8.57 Million USD | -7.94% |
| 2018 FY | - USD | -28.83% |
| 2018 Q4 | -10.77 Million USD | -32.45% |
| 2018 Q1 | -7.94 Million USD | -0.11% |
| 2018 Q3 | -8.13 Million USD | 5.15% |
| 2017 Q3 | -6.5 Million USD | -1.36% |
| 2017 Q4 | -7.93 Million USD | -22.09% |
| 2017 FY | - USD | -29.39% |
| 2017 Q1 | -6.29 Million USD | 0.0% |
| 2017 Q2 | -6.41 Million USD | -1.83% |
| 2016 FY | - USD | 0.0% |
| Name | EBITDA | EBITDA Difference |
|---|---|---|
| Abbott Laboratories | 10.46 Billion USD | 100.328% |
| Allurion Technologies Inc. | -69.03 Million USD | 50.23% |
| Artivion, Inc. | 38.14 Million USD | 190.077% |
| Avanos Medical, Inc. | 53.2 Million USD | 164.581% |
| Butterfly Network, Inc. | -124.84 Million USD | 72.48% |
| Butterfly Network, Inc. | -124.84 Million USD | 72.48% |
| Bio-Rad Laboratories, Inc. | -608.26 Million USD | 94.352% |
| Boston Scientific Corporation | 3.45 Billion USD | 100.995% |
| Perspective Therapeutics, Inc. | -14.83 Million USD | -131.547% |
| CONMED Corporation | 182.18 Million USD | 118.858% |
| Edwards Lifesciences Corporation | 1.76 Billion USD | 101.944% |
| Paragon 28, Inc. | -36.61 Million USD | 6.164% |
| Glaukos Corporation | -82.11 Million USD | 58.16% |
| Globus Medical, Inc. | 418.23 Million USD | 108.215% |
| Inspire Medical Systems, Inc. | -17.06 Million USD | -101.389% |
| Integer Holdings Corporation | 282.05 Million USD | 112.181% |
| Medtronic plc | 9.05 Billion USD | 100.379% |
| Nevro Corp. | -78.31 Million USD | 56.127% |
| Owlet, Inc. | -27.48 Million USD | -24.985% |
| Penumbra, Inc. | 111.99 Million USD | 130.677% |
| Vicarious Surgical Inc. | -69.19 Million USD | 50.345% |
| Smith & Nephew plc | 979 Million USD | 103.509% |
| Sonendo, Inc. | -54.76 Million USD | 37.268% |
| STERIS plc | 1.41 Billion USD | 102.433% |
| Stryker Corporation | 5.16 Billion USD | 100.666% |
| Zimmer Biomet Holdings, Inc. | 2.44 Billion USD | 101.403% |